Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Introduction Since the soluble receptor activator of the NF-kappaB ligand (sRANKL) as well as the endogenous anti-resorptive cytokine osteoprotegerin (OPG) are produced by osteoblasts and given that these cells undergo significant changes during antiresorptive treatment, we hypothesized that treatment with bisphosphonates (BP) would be accompanied by changes in serum OPG and sRANKL levels.Methods In a prospective, randomized controlled trial of previously untreated postmenopausal women with osteoporosis, oral BP therapy (daily doses of either 10 mg alendronate or 5 mg risedronate) in combination with calcium/vitamin D was compared to calcium/vitamin D treatment alone (control group). Follow-up at 2, 6 and 12 months was completed for 56 patients. Standardized spinal X-rays were performed at baseline, and DEXA measurements at the femoral neck and trochanter were made at baseline and after 1 year. Serum OPG and sRANKL levels were measured with a polyclonal antibody-based ELISA system.Results After 1 year, there was a non-significant loss in neck and trochanteric bone mineral density (BMD) in the CTR group and a mean increase of 3.3% and 4.6% in the combined BP group (both p<0.0001), respectively. Serum levels of C-terminal telopeptides of type I collagen (sCTX) and osteocalcin decreased by 12% and 10% at 12 months in the CTR group and by 43% and 23% in the combined BP group, respectively (all significant). OPG serum levels in the CTR group decreased significantly by 9% at 2 months (p<0.005) and remained below pre-treatment levels at later time points. Both the alendronate- and risedronate-treated patient groups showed unaltered OPG levels after 2 months, but they had significantly increased serum levels at 6 and 12 months. Levels of sRANKL were unchanged throughout the treatment period. Univariate regression analysis demonstrated that changes in serum OPG levels after 12 months of BP treatment were positively and better correlated to BMD changes (trochanter: r=0.59, p<0.0001; neck: r=0.50, p<0.001) than those of sCTX, which showed the expected negative correlation to BMD change (trochanter: r=-0.35, p=0.03; neck: r=-0.23, p=0.16). With multiple regression analyses at 12 months, R2 values for 1-year changes in trochanteric BMD of 0.33 (OPG alone) and 0.23 (sCTX alone) were significantly improved to the 0.57 when OPG and sCTX changes were combined (p<0.001). Results for the femoral neck were also statistically significant R2=0.35, p<0.001). BMD and OPG changes in the CTR group were not correlated with each other.Conclusions We conclude that with BP treatment, changes in serum OPG levels, unlike changes in sCTX levels, are positively correlated to changes in BMD response. The BP-related changes in serum OPG levels during treatment could result from effects on osteoclastogenesis and osteoclast apoptosis as well as from a direct stimulatory effect on osteoblastic OPG production. These changes in OPG levels may be used to predict the individual response of patients to BP treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, a study of oral bisphosphonates in postmenopausal women found a positive correlation between changes in serum OPG levels and BMD response (390).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [390]
Citations
Cites
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691 · cited 1×
“[31], a prevalent vertebral fracture was diagnosed when there was a ≥20% reduction in any of the anterior, middle or posterior height ratios of the vertebral body compared to undeformed adjacent vertebrae.”
BackgroundLips, P. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.4.0437 · Cited by 2,118 · cited 1×
“The decrease in PTH, whichwas on the order of 10%with calcium/ vitamin D supplementation, suggests the presence of a mild deficiency of vitamin D in our patients at baseline [41].”
BackgroundLuckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Dr. Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176 · cited 1×
“pathway [1] and increase the production of Apppi, an ATP”
BackgroundBisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D. G., Mundy, G. R., & Dr. Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,040 · cited 1×
“BP have a direct antiresorptive effect on osteoclasts [37] that feeds back on osteoblast activity by decreasing the proliferation and differentiation of osteoblasts via a coupling mechanism that is still poorly defined.”
BackgroundRole of osteoblasts in hormonal control of bone resorption—A hypothesis
Rodan, G. A., & Martin, T. J. (1981) · Calcified Tissue International · doi:10.1007/bf02409454 · Cited by 982
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890 · cited 1×
“Recent reports propose that BP are capable of stimulating differentiation and inhibiting proliferation of the human fetal osteoblastic lineage cell line hFOB [10] and of decreasing osteoblastic apoptosis in murine vertebral cancellous bone cells [11].”
BackgroundBoivin, G. Y., Chavassieux, P. M., Santora, A. C., Yates, J., & Meunier, P. J. (2000) · Bone · doi:10.1016/s8756-3282(00)00376-8 · Cited by 574
Chavassieux, P. M., Arlot, M. E., Reda, C., Wei, L., Yates, A. J., & Meunier, P. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119668 · Cited by 523 · cited 1×
“This phenomenon is also reflected by the finding of an 80–90% decrease in the mineralizing surface of transiliac bone specimens 6 and 12 months after the initiation of BP treatment [38, 39].”
Result
Research works printed but not linked: 2
- Mönkkönen H, Lehenkari PP, Kellinsalmi M (2004) A new mechanism of action for bisphosphonates: apppi dedicated cytotoxicity of N-BPs. Bone 34:S66–S67
- Sankaralingam S, Frost M, Fogelman I, Hampson G (2003) Early changes in serum osteoprotegerin (OPG) correlates with changes in bone mineral density following treatment with risedronate in post-menopausal women with osteoporosis (Abstract). J Bone Miner Res 18:S158
Cited by
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003376.pub3 · Cited by 499
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001155.pub2 · Cited by 401
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004523.pub3 · Cited by 211
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
Baud’huin, M., Lamoureux, F., Duplomb, L., Rédini, F., & Heymann, D. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7104-0 · Cited by 170
Boanini, E., Torricelli, P., Gazzano, M., Giardino, R., & Bigi, A. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.10.040 · Cited by 156
Burch, J., Rice, S., Yang, H., Neilson, A., Stirk, L., Francis, R., Holloway, P., Selby, P., & Craig, D. (2014) · Health Technology Assessment · doi:10.3310/hta18110 · Cited by 132
Pathophysiological roles of osteoprotegerin (OPG)
Reid, P., & Holen, I. (2008) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2008.06.004 · Cited by 143
Prevention and treatment of osteoporosis in inflammatory bowel disease
Lichtenstein, G. R., Sands, B. E., & Pazianas, M. (2006) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200608000-00016 · Cited by 100
Ohba, T., Cole, H., Cates, J., Slosky, D., Haro, H., Ando, T., Schwartz, H. S., & Schoenecker, J. G. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2182 · Cited by 93
“Circulating markers of bone turnover and resorption are indicators of bisphosphonate activity in osteoporosis and metastatic bone disease.((23,24)) Therefore, we measured plasma OPG and soluble RANKL (sRANKL) levels using ELISA.”
MethodWells, G. A., Hsieh, S., Zheng, C., Peterson, J., Liu, W., Kelly, S., & Tugwell, P. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004523.pub4 · Cited by 91
Tsubaki, M., Satou, T., Itoh, T., Imano, M., Yanae, M., Kato, C., Takagoshi, R., Komai, M., & Nishida, S. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.05.002 · Cited by 78
Martini, G., Gennari, L., Merlotti, D., Salvadori, S., Franci, M. B., Campagna, S., Avanzati, A., De Paola, V., Valleggi, F., & Nuti, R. (2007) · Bone · doi:10.1016/j.bone.2006.08.003 · Cited by 72
“Our results are also consistent with a recent study that demonstrated and increase in OPG at 6 and 12 months in bisphosphonate-treated osteoporotic women [50] and suggest a stimulatory effects of amino bisphosphonates on OPG production.”
ResultGenetic epidemiology of age-related osteoporosis and its clinical applications
Cheung, C., Xiao, S., & Kung, A. W. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.106 · Cited by 72
“In addition, a positive correlation of serum OPG level with BMD response to bisphosphonate treatment was reported, suggesting a potential role for serum OPG level in monitoring individual response to bisphosphonate treatment”
BackgroundD’Amelio, P., Grimaldi, A., Bella, S. D., Tamone, C., Brianza, S., Ravazzoli, M., Bernabei, P., Cristofaro, M. A., Pescarmona, G., & Isaia, G. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.071031 · Cited by 67
“In the serum, we measured the levels of total sRANKL (Apotech; Apotech Corp. and Immunodiagnostik) to exclude possible influence caused by a variation in OPG level after therapy, as suggested by Dobnig et al.(25) Each measurement was performed in duplicate for each patient.”
BackgroundMethodResultInfluentialWagner, D., & Fahrleitner‐Pammer, A. (2010) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-010-0818-x · Cited by 60
Self-citationDobnig, H., Piswanger-Sölkner, J. C., Obermayer-Pietsch, B. M., Tiran, A., Groselj‐Strele, A., Maier, E., Maritschnegg, P., Riedmüller, G., Brueck, C. C., & Fahrleitner‐Pammer, A. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2079 · Cited by 53
Self-citationD’Amelio, P., Roato, I., D’Amico, L., Veneziano, L., Suman, E., Sassi, F., Bisignano, G., Ferracini, R., Gargiulo, G., Castoldi, F., et al. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1496-7 · Cited by 50
“The increase in OPG may be interpreted as an attempt to inhibit RANKL, and as a sign of increased bone turnover [7, 31].”
BackgroundAlendronate reduces osteoclast precursors in osteoporosis
D’Amelio, P., Grimaldi, A., Cristofaro, M. A., Ravazzoli, M., Molinatti, P. A., Pescarmona, G., & Isaia, G. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1129-1 · Cited by 57
“It has been suggested that BPs act both directly on OCs through internalization and through their effect on OC recruitment by nonactive precursors and through the inhibition of pro-osteoclastogenic cytokines [12, 13 ].”
BackgroundResultInfluentialPepe, J., Petrucci, M. T., Mascia, M. L., Piemonte, S., Fassino, V., Romagnoli, E., & Minisola, S. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9145-2 · Cited by 49
“Regarding the mechanism of action of alendronate, one cannot also exclude a direct effect on the RANKL/OPG system; it is worth emphasizing that this effect has been observed also in postmenopausal osteoporotic patients treated with the same drug [38].”
BackgroundBisphosphonates pharmacology and use in the treatment of osteoporosis
Diab, D. L., Watts, N. B., & Miller, P. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00074-5 · Cited by 48
Reduced Osteoclastogenesis and RANKL Expression in Marrow from Women Taking Alendronate
Eslami, B., Zhou, S., van Eekeren, I. C. M., LeBoff, M. S., & Glowacki, J. (2011) · Calcified Tissue International · doi:10.1007/s00223-011-9473-5 · Cited by 44
“[34] demonstrated a significant increase in serum levels of OPG in osteoporotic women who were treated with AL or risedronate for 6 and 12 months.”
BackgroundZhu, S., Häussling, V., Aspera-Werz, R. H., Chen, T., Braun, B., Weng, W., Histing, T., & Nussler, A. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010053 · Cited by 42
“The inhibition of osteoclastic differentiation via the mevalonate pathway is recognized as the main mechanism of BPs [52], but recent evidence indicates that BPs also regulate essential molecules related to osteoclastogenesis, such as the RANKL/RANK/OPG pathway [53,54].”
BackgroundGossiel, F., Hoyle, C., McCloskey, E. V., Naylor, K. E., Walsh, J., Peel, N. F. A., & Eastell, R. (2016) · Bone · doi:10.1016/j.bone.2016.08.010 · Cited by 47
Traditional and Novel Bone Remodeling Markers in Premenopausal and Postmenopausal Women
Botella, S., Restituto, P., Monreal, I., Colina, I., Calleja, A., & Varo, N. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2264 · Cited by 41
“Markers of specific bone-signaling pathways, such as OPG, have been shown to correlate with the variation of BMD in postmenopausal women treated with risedronate and alendronate (46).”
BackgroundToll gates to periodontal host modulation and vaccine therapy
Hajishengallis, G. (2009) · Periodontology 2000 · doi:10.1111/j.1600-0757.2009.00304.x · Cited by 38
“Bisphosphonates appear to reduce the RANKL/OPG ratio, mostly by increasing OPG levels (47,146,218).”
BackgroundRANKL inhibition for the management of patients with benign metabolic bone disorders
Anastasilakis, A. D., Toulis, K. A., Pοlyzos, S. A., & Terpos, E. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903048929 · Cited by 39
“sRANKL response to bisphosphonate therapy also varies from no change [122] to decrease [113,137].”
BackgroundKang, J., Keller, J. J., & Lin, H. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1894-0 · Cited by 36
Jacobs, J. W. G., de Nijs, R. N. J., Lems, W. F., Geusens, P., Laan, R., Huisman, A.-M., Algra, A., Buskens, E., Hofbauer, L. C., Oostveen, A. C. M., et al. (2007) · PubMed · Cited by 36
Self-citationOsteonecrosis of the jaw and bisphosphonate use in breast cancer patients
Kyrgidis, Α., Triaridis, S., Vahtsevanos, K., & Antoniades, K. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.74 · Cited by 34
Impact of Cigarette Smoking on the Risk of Osteoporosis in Inflammatory Bowel Diseases
Ratajczak, A. E., Szymczak‐Tomczak, A., Rychter, A. M., Zawada, A. E., Dobrowolska, A., & Krela‐Kaźmierczak, I. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071515 · Cited by 40
Anastasilakis, A. D., Goulis, D. G., Pοlyzos, S. A., Gerou, S., KOUKOULIS, G. N., Efstathiadou, Z. A., Kita, M. D., & Avramidis, A. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01768.x · Cited by 32
Direct effects of osteoprotegerin on human bone cell metabolism
Grundt, A., Grafe, I., Liegibel, U. M., Sommer, U., Nawroth, P. P., & Kasperk, C. H. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.09.026 · Cited by 34
Up-regulation of multiple proteins and biological processes during maxillary expansion in rats
Ma, J., Yun-xia, W., Zhang, W., Smales, R. J., Huang, Y., Pan, Y., & Wang, L. (2008) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-9-37 · Cited by 23
Kyrgidis, Α., Triaridis, S., & Αντωνιάδης, Κ. (2009) · Bioscience hypotheses · doi:10.1016/j.bihy.2009.02.005 · Cited by 23
Bisphosphonates in the treatment of metabolic bone diseases
Arantes, H. P., da Silva, A. G., & Lazaretti‐Castro, M. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000200017 · Cited by 22
“Further trials revealed that ibandronate 150 mg/month orally and ibandronate 3 mg quarterly intravenously (IV) resulted in greater increases in BMD compared with the daily oral regimen (22).”
BackgroundInfluentialComparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice
Liu, J., Xu, K., Wen, G., Guo, H., San, L., Wu, X., Dai, R.-C., Sheng, Z., & Liao, E. (2008) · Bone · doi:10.1016/j.bone.2008.01.010 · Cited by 20
“bisphosphonate can increase the BMD of the femoral neck and the trochanter in PMOP and may elevate the serum OPG levels [38].”
BackgroundDündar, Ü., Kavuncu, V., Çiftçi, İ. H., Evcik, D., Solak, Ö., & Çakır, T. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0055-9 · Cited by 23
“Differences between the populations studied (some studies consisted of early postmenopausal women with rheumatoid arthritis [23], some consisted of late postmenopausal women [21, 22], and others of both older (mean age [60 years old) male and female patients with Paget’s disease [24, 26]) and inherent limitations in t…”
BackgroundInfluentialNatsag, J., Kendall, M. A., Sellmeyer, D. E., McComsey, G., & Brown, T. T. (2015) · HIV Medicine · doi:10.1111/hiv.12291 · Cited by 19
Sewerynek, E., Horst-Sikorska, H., Stępień-Kłos, W., Antkowiak, A., Janik, M., Cieślak, K., Marcinkowska, M., Cegłowska, A., & Stuss, M. (2013) · Archives of Medical Science · doi:10.5114/aoms.2013.34575 · Cited by 19
“However, there are no conclusive data on the relationship of these compounds with the effectiveness of different forms of therapy [40, 41] or fragility fractures [42].”
BackgroundMabilleau, G., Pascaretti‐Grizon, F., Baslé, M. F., & Chappard, D. (2011) · Cytokine · doi:10.1016/j.cyto.2011.11.014 · Cited by 20
“Involvement of the RANKL/RANK pathway has been recently reported in bone disorders characterised by increased bone resorption such as post-menopausal osteoporosis [12,13], rheumatoid arthritis (RA) [14,15] and bone metastases [16,17].”
Abe, T., Sato, T., Kokabu, S., Hori, N., Shimamura, Y., Sato, T., & Yoda, T. (2016) · Cytokine · doi:10.1016/j.cyto.2016.03.012 · Cited by 20
Choi, H.-J., Im, J., & Kim, S.-H. (2008) · Maturitas · doi:10.1016/j.maturitas.2008.05.003 · Cited by 18
Stuss, M., Sewerynek, E., Król, I., Stępień-Kłos, W., & Jędrzejczyk, S. (2016) · Endokrynologia Polska · doi:10.5603/ep.a2016.0014 · Cited by 18
“001) was demonstrated, OPG and BMD of the femoral neck and trochanter after six and 12 months of therapy with bisphosphonates [28], which we did not see in our study.”
BackgroundNeumann, E., & Schett, G. A. (2007) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-007-0182-4 · Cited by 18
Bisphosphonates: Pharmacology and Use in the Treatment of Osteoporosis
Miller, P. D. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50076-8 · Cited by 20
Reyes‐García, R., Muñoz‐Torres, M., García, D. F., Mezquita‐Raya, P., Salcedo, J. A. G., & Luna, J. D. D. (2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181ac0cc1 · Cited by 17
“OPG changes after a 1-year treatment were positively correlated to BMD changes at femoral neck.(14)”
MethodResultPharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders.
SINIGAGLIA, L., VARENNA, M., & Casari, S. (2007) · PubMed · Cited by 17
Wu, X., Wu, X., Xie, H., Zhang, H., Luo, X., Liu, S., Peng, Y., Dai, R.-C., & Liao, E.-Y. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2007.11.024 · Cited by 13
Malliga, D.-E., Wagner, D., & Fahrleitner‐Pammer, A. (2011) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-011-0022-7 · Cited by 16
“interaction between OPG, RANKL and RANK [25].”
Self-citationFujita, H., Kurokawa, K., Ogino, T., Ono, M., Yamamoto, M., Oka, T., Nakanishi, T., Kobayashi, N., Tanaka, N., Ogawa, T., et al. (2011) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2011.00685.x · Cited by 12
Shimano, R. C., Macedo, A. P., Falcai, M. J., Ervolino, E., Shimano, A. C., & Issa, J. P. M. (2014) · Microscopy Research and Technique · doi:10.1002/jemt.22363 · Cited by 15
Zhang, J., Park, J., Lee, J., Kwon, Y., & Kim, E.-C. (2017) · Clinical Oral Investigations · doi:10.1007/s00784-017-2291-z · Cited by 12
Wells, G. A., Hsieh, S., Peterson, J., Zheng, C., Kelly, S., Shea, B., & Tugwell, P. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001155.pub3 · Cited by 16
“Dobnig 2006 {published data only} Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A, Dobnig H, et al.Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.”
Piatek, S., Adolf, D., Wex, T., Halangk, W., Klose, S., Westphal, S., Amthauer, H., & Winckler, S. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.01.005 · Cited by 13
“Other studies showed a negative correlation [5,13,18,24,36].”
Karadağ‐Saygı, E., Akyüz, G., Bizargity, P., & Ay, P. (2011) · Gynecological Endocrinology · doi:10.3109/09513590.2011.579657 · Cited by 11
“, serum OPG levels correlated positively with serum CTX at the beginning of bisphosphonate treatment [3], whereas other investigators found no relationship [11,12,14].”
BackgroundInfluentialNamazi, H. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318180721d · Cited by 9
Özden, F. O., Sakallıoğlu, E. E., Demir, E., Bilgici, B., Tunçel, Ö. K., Gökosmanoğlu, F., & Atmaca, A. A. (2017) · Journal of Oral Science · doi:10.2334/josnusd.16-0241 · Cited by 8
“BP affects the RANKL/OPG system by increasing OPG production and decreasing RANKL production (19,20).”
BackgroundYang, Y., Yang, M., Su, X., & Xie, F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1422062 · Cited by 7
Hajisadeghi, S., Naghsh, N., Razavi, S. M., Minaiyan, M., Shahabooei, M., Birang, R., & Behfarnia, P. (2016) · Dental Research Journal · doi:10.4103/1735-3327.197034 · Cited by 7
“A number of drugs such as bisphosphontes,[10,11] esteriods,[12] nonesteroidal anti‐inflammatory drugs,[13,14] and chemically modified teracyclines[15] are recognized for interaction with these complicated mechanisms in different stages, although the exact mechanisms of these agents have not been exactly described.”
BackgroundDiab, D. L., Watts, N. B., & Miller, P. D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00080-7 · Cited by 7
Si Inhibited Osteoclastogenesis: The Role of Fe and the Fenton Reaction
Li, Y., Radu, A.-M., Rezaei, A., Turner, J., Shakib, K., Obata, A., Kasuga, T., & Jell, G. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501086 · Cited by 6
Ledoux, C., Boaretti, D., Sachan, A., Müller, R., & Collins, C. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.901720 · Cited by 9
Kramer, J. M., & Fantasia, J. E. (2011) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-011-9083-9 · Cited by 5
Bisphosphonate: A Novel Treatment for Pigmented Villonodular Synovitis
Namazi, H. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9797-6 · Cited by 4
“In particular, the cytoskeleton is vital for maintaining the ruffled border that is required for contact between a resorbing osteoclast and a bone surface.12,13 Also, data obtained in recent studies have demonstrated that bisphosphonates stimulate the OPG production by osteoblasts, which can lead to a significant redu…”
ResultAdjuvant therapy with 1% alendronate gel for experimental periodontitis treatment in rats
de Campos, N., Buischi, Y. D. P., Loomer, P. M., Bromage, T. G., Ervolino, E., Fucini, S. E., Pola, N. M., Pirovani, B. O., Morábito, M. J. S. D., de Almeida, J. M., et al. (2021) · Journal of Periodontal & Implant Science · doi:10.5051/jpis.2100700035 · Cited by 3
Singh, M., Sabharwal, S., Jamwal, N., Gupta, M., & Garg, K. (2025) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_108_25 · Cited by 2
“[8] DEN (AMG‑162) is a type of human monoclonal immunoglobulin G2 antibody that is highly specific and has a strong affinity for human RANKL.”
Francis, R. M. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6231-8.10069-8 · Cited by 2
Neue pathophysiologische Stoffwechselwege in der Osteoporose: Zukünftige innovative Therapieansätze?
Neumann, E. (2006) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-006-0086-8 · Cited by 4
Namazi, H. (2009) · Journal of Pediatric Orthopaedics · doi:10.1097/bpo.0b013e3181b2bad6 · Cited by 2
“In addition, data obtained in recent studies have showed that pamidronate stimulates OPG ACC_cproduction by osteoblasts, which can lead to a significant reduction in RANKL.(10,11) 1,25(OH)2D3 activates rapid, plasma membrane-initiated signaling events and longer-term nuclear receptor-mediated pathways in osteoblastic…”
ResultA Study of the Relationship Between Kidneys, Bones, and Teeth in Eastern-Western Medicine
Lee, E.-B., & Han, S. Y. (2024) · 동의생리병리학회지 · doi:10.15188/kjopp.2024.10.38.5.187 · Cited by 1
Sievers, N. (2012) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-1628 · Cited by 4
Risedronate improves bone mineral density in Crohn's disease: A complementary mechanism
Namazi, H. (2012) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2012.03.014
New strategies of treatment of postmenopausal osteoporosis
Sobczuk, A., Sobczuk, K., & Pertyński, T. (2011) · Menopause Review/Przegląd Menopauzalny
Neumann, E. (2006) · Zeitschrift für Rheumatologie
Age-dependent musculoskeletal changes during mechanical unloading with bisphosphonate treatment
Orr, S. V., Gilmore, N. K., Pathak, S. J., Edan, H. A., Langer, H. T., Baar, K., & Christiansen, B. (2026) · Bone · doi:10.1016/j.bone.2026.117924
Metadata
- Authors
- Dobnig, H., Hofbauer, L. C., Viereck, V., Obermayer-Pietsch, B., & Fahrleitner-Pammer, A.
- Affiliations
- University of Graz (AT)
- Philipps University of Marburg (DE)
- University of Göttingen (DE)
- Corresponding author
- Dobnig, H.
- Venue
- Osteoporosis International
- Published
- 2006-01-25
- Volume
- 17
- Issue
- 5
- Pages
- 693-703
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2075929809
- Cited by
- 76
- References
- 42
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2022: 2 · 2021: 2 · 2020: 2 · 2017: 2 · 2016: 4 · 2015: 1 · 2014: 2 · 2013: 4 · 2012: 4
- FWCI
- 11.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- RANK ligand, osteoprotegerin, bisphosphonates, alendronate, risedronate, osteoporosis, bone mineral density, postmenopausal women, bone resorption, osteocalcin, C-terminal telopeptide of type I collagen, calcium and vitamin D supplementation, antiresorptive therapy, serum biomarkers, femoral neck
- MeSH terms
- Risedronic Acid, Aged, Female, Hip, Humans, Osteoporosis, Prospective Studies, Etidronic Acid, Absorptiometry, Photon, Bone Density, Osteocalcin, Bone Remodeling, Postmenopause, Alendronate, Collagen Type I, Bone Density Conservation Agents, Osteoprotegerin, RANK Ligand
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.